Compare SHO & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHO | PHVS |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.4B |
| IPO Year | 2004 | 2020 |
| Metric | SHO | PHVS |
|---|---|---|
| Price | $12.77 | $33.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 14 |
| Target Price | $12.40 | ★ $57.82 |
| AVG Volume (30 Days) | ★ 3.1M | 621.8K |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $1,115,167,000.00 | N/A |
| Revenue This Year | $4.56 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $29.64 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.69 | $23.01 |
| 52 Week High | $13.08 | $43.25 |
| Indicator | SHO | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 60.39 | 52.95 |
| Support Level | $12.19 | $32.27 |
| Resistance Level | $13.08 | $36.36 |
| Average True Range (ATR) | 0.28 | 1.50 |
| MACD | -0.05 | 0.15 |
| Stochastic Oscillator | 61.80 | 49.74 |
Sunstone Hotel Investors Inc is a real estate investment trust that acquires, owns, manages, and renovates the full-service hotel and select-service hotel properties across various states in the United States. Its firm's portfolio consists upper upscale and luxury hotels located in convention, resort destination and urban markets. Its majority of the hotels operate under a brand owned by Marriott, Hilton, Hyatt, Four Seasons or Montage. It operates geographically in California which generates the majority of its revenue; Florida; and Hawaii. The company's sole source of income is hotel revenue from its Hotel Ownership Segment.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks. The company is also running open-label extension studies in both on-demand (RAPIDe-2) and prophylactic (CHAPTER-4) settings to collect long-term safety and efficacy data in HAE patients.